Phenotype
|
Fish
|
Conditions
|
Figures
|
whole organism mmp9 expression amount, ameliorated
|
AB + MO1-spint1a
|
hypotonic, chemical treatment by environment: mannitol
|
Fig 1
from Hatzold et al., 2023
|
epidermis potentially cancerous lesions amount, ameliorated
|
AB + MO1-spint1a
|
hypotonic, chemical treatment by environment: mannitol
|
Fig 1
from Hatzold et al., 2023
|
whole organism mmp9 expression increased amount, abnormal
|
AB + MO1-spint1a
|
hypotonic
|
Fig 1
from Hatzold et al., 2023
|
epidermis potentially cancerous lesions increased amount, abnormal
|
AB + MO1-spint1a
|
hypotonic
|
Fig 1
from Hatzold et al., 2023
|
epidermal basal stratum cell protruding out of epidermis, abnormal
|
WT + MO1-spint1a
|
control
|
Fig. 5
from Armistead et al., 2020
|
epidermis development disrupted, abnormal
|
WT + MO1-spint1a
|
standard conditions
|
Fig. 3
from Carney et al., 2007
|
keratinocyte mislocalised, abnormal
|
WT + MO1-spint1a
|
standard conditions
|
Fig. 3
from Carney et al., 2007
|
whole organism mmp13a.1 expression increased amount, abnormal
|
WT + MO1-spint1a
|
standard conditions
|
Fig. 7
from Schepis et al., 2018
|
peridermal cell protruding out of epidermis, abnormal
|
WT + MO1-spint1a
|
control
|
Fig. 5
from Armistead et al., 2020
|
whole organism mmp9 expression increased amount, abnormal
|
WT + MO1-spint1a
|
standard conditions
|
Fig. 7
from Schepis et al., 2018
|
integument cell aggregated, abnormal
|
WT + MO1-spint1a
|
standard conditions
|
Fig. 2
from Schepis et al., 2018
|
epidermal basal stratum keratinocyte aggregated, abnormal
|
WT + MO1-spint1a
|
standard conditions
|
Fig. 3
from Carney et al., 2007
|
chorion accumulation keratinocyte, abnormal
|
WT + MO1-spint1a
|
standard conditions
|
Fig. 3
from Carney et al., 2007
|
keratinocyte disorganized, abnormal
|
WT + MO1-spint1a
|
standard conditions
|
Fig. 5
from Carney et al., 2007
|
whole organism il1b expression increased amount, abnormal
|
WT + MO1-spint1a
|
standard conditions
|
Fig. 7
from Schepis et al., 2018
|
epithelial cell protruding out of epidermal superficial stratum, abnormal
|
cy22Tg + MO1-spint1a
|
standard conditions
|
Fig. 3
from Schepis et al., 2018
|
epidermal basal stratum cell population proliferation increased occurrence, abnormal
|
cy34Tg + MO1-spint1a
|
standard conditions
|
Fig. 7,
Fig. 8
from Schepis et al., 2018
|
epidermal basal stratum cell population proliferation occurrence, ameliorated
|
cy34Tg + MO1-spint1a
|
chemical treatment: matrix metalloproteinase inhibitor
|
Fig. 7
from Schepis et al., 2018
|
epithelial cell protruding out of epidermal superficial stratum, abnormal
|
cy34Tg + MO1-spint1a
|
standard conditions
|
Fig. 7,
Fig. 8
from Schepis et al., 2018
|
epidermal basal stratum cell population proliferation occurrence, ameliorated
|
cy34Tg + MO1-spint1a
|
chemical treatment: PD 168393
|
Fig. 8
from Schepis et al., 2018
|
epidermal superficial stratum cell population proliferation increased occurrence, abnormal
|
cy34Tg + MO1-spint1a
|
chemical treatment: PD 168393
|
Fig. 8
from Schepis et al., 2018
|
epidermal superficial stratum cell population proliferation increased occurrence, exacerbated
|
cy34Tg + MO1-spint1a
|
chemical treatment: matrix metalloproteinase inhibitor
|
Fig. 7
from Schepis et al., 2018
|
epithelial cell protruding out of epidermal superficial stratum, abnormal
|
cy34Tg + MO1-spint1a
|
chemical treatment: PD 168393
|
Fig. 8
from Schepis et al., 2018
|
epidermal superficial stratum cell population proliferation increased occurrence, abnormal
|
cy34Tg + MO1-spint1a
|
standard conditions
|
Fig. 6 ,
Fig. 7,
Fig. 8
from Schepis et al., 2018
|
epidermal basal stratum cell motility increased occurrence, abnormal
|
cy34Tg + MO1-spint1a
|
standard conditions
|
Fig. 6
from Schepis et al., 2018
|
epidermal basal stratum cytoplasm ab2-cdh1 labeling mislocalised, abnormal
|
cy34Tg + MO1-spint1a
|
standard conditions
|
Fig. 5
from Schepis et al., 2018
|
epidermal basal stratum cell-cell adhesion process quality, ameliorated
|
la213Tg; mu271Tg + MO1-spint1a
|
chemical treatment: matrix metalloproteinase inhibitor
|
Fig. 7
from Schepis et al., 2018
|
epidermal basal stratum cell-cell adhesion process quality, ameliorated
|
la213Tg; mu271Tg + MO1-spint1a
|
chemical treatment: PD 168393
|
Fig. 8
from Schepis et al., 2018
|
epidermal basal stratum cell motility increased occurrence, abnormal
|
la213Tg; mu271Tg + MO1-spint1a
|
standard conditions
|
Fig. 4
from Schepis et al., 2018
|
epidermal basal stratum cell-cell adhesion decreased process quality, abnormal
|
la213Tg; mu271Tg + MO1-spint1a
|
control
|
Fig. 4 ,
Fig. 7,
Fig. 8
from Schepis et al., 2018
|
whole organism mmp13a.1 expression amount, ameliorated
|
f2rl1.2sfc18b/sfc18b + MO1-spint1a
|
standard conditions
|
Fig. 7
from Schepis et al., 2018
|
integument cell aggregated, ameliorated
|
f2rl1.2sfc18b/sfc18b + MO1-spint1a
|
standard conditions
|
Fig. 2
from Schepis et al., 2018
|
whole organism il1b expression amount, ameliorated
|
f2rl1.2sfc18b/sfc18b + MO1-spint1a
|
standard conditions
|
Fig. 7
from Schepis et al., 2018
|
whole organism mmp9 expression amount, ameliorated
|
f2rl1.2sfc18b/sfc18b + MO1-spint1a
|
standard conditions
|
Fig. 7
from Schepis et al., 2018
|
keratinocyte proliferation increased occurrence, abnormal
|
spint1ahi2217Tg/hi2217Tg + MO1-spint1a + MO1-spint1b
|
standard conditions
|
Fig. 4
from Carney et al., 2007
|
integument cell aggregated, ameliorated
|
WT + MO1-f2rl1.2 + MO1-spint1a
|
standard conditions
|
Fig. 2
from Schepis et al., 2018
|
chorion accumulation keratinocyte, abnormal
|
WT + MO1-spint1a + MO1-spint1b
|
standard conditions
|
Fig. 3
from Carney et al., 2007
|
epidermal basal stratum keratinocyte aggregated, abnormal
|
WT + MO1-spint1a + MO1-spint1b
|
standard conditions
|
Fig. 3
from Carney et al., 2007
|
keratinocyte disorganized, abnormal
|
WT + MO1-spint1a + MO1-spint1b
|
standard conditions
|
Fig. 5
from Carney et al., 2007
|
keratinocyte mislocalised, abnormal
|
WT + MO1-spint1a + MO1-spint1b
|
standard conditions
|
Fig. 3
from Carney et al., 2007
|
epidermis development disrupted, abnormal
|
WT + MO1-spint1a + MO1-spint1b
|
standard conditions
|
Fig. 3
from Carney et al., 2007
|
integument cell aggregated, ameliorated
|
WT + MO1-spint1a + MO1-st14a
|
standard conditions
|
Fig. 2
from Schepis et al., 2018
|
whole organism mmp13a.1 expression amount, ameliorated
|
WT + MO1-spint1a + MO1-st14a
|
standard conditions
|
Fig. 7
from Schepis et al., 2018
|
peridermal cell protruding out of epidermis, ameliorated
|
WT + MO1-spint1a + MO1-st14a
|
control
|
Fig. 5
from Armistead et al., 2020
|
whole organism il1b expression amount, ameliorated
|
WT + MO1-spint1a + MO1-st14a
|
standard conditions
|
Fig. 7
from Schepis et al., 2018
|
whole organism mmp9 expression amount, ameliorated
|
WT + MO1-spint1a + MO1-st14a
|
standard conditions
|
Fig. 7
from Schepis et al., 2018
|
epidermal basal stratum cell protruding out of epidermis, ameliorated
|
WT + MO1-spint1a + MO1-st14a
|
control
|
Fig. 5
from Armistead et al., 2020
|
peridermal cell protruding out of epidermis, exacerbated
|
WT + MO1-spint1a + MO2-itga3b
|
control
|
Fig. 5
from Armistead et al., 2020
|
epidermal basal stratum cell protruding out of epidermis, exacerbated
|
WT + MO1-spint1a + MO2-itga3b
|
control
|
Fig. 5
from Armistead et al., 2020
|
caudal fin epidermal cell aggregated, exacerbated
|
WT + MO1-spint1a + MO2-itga3b
|
control
|
Fig. 5
from Armistead et al., 2020
|
peridermal cell protruding out of epidermis, exacerbated
|
WT + MO1-spint1a + MO3-lama5
|
control
|
Fig. 5
from Armistead et al., 2020
|
epidermal basal stratum cell protruding out of epidermis, exacerbated
|
WT + MO1-spint1a + MO3-lama5
|
control
|
Fig. 5
from Armistead et al., 2020
|
caudal fin epidermal cell aggregated, exacerbated
|
WT + MO1-spint1a + MO3-lama5
|
control
|
Fig. 5
from Armistead et al., 2020
|
caudal fin epidermal cell aggregated, ameliorated
|
WT + MO1-spint1a + MO1-st14a + MO2-itga3b
|
control
|
Fig. 5
from Armistead et al., 2020
|
epidermal basal stratum cell protruding out of epidermis, ameliorated
|
WT + MO1-spint1a + MO1-st14a + MO2-itga3b
|
control
|
Fig. 5
from Armistead et al., 2020
|
peridermal cell protruding out of epidermis, ameliorated
|
WT + MO1-spint1a + MO1-st14a + MO2-itga3b
|
control
|
Fig. 5
from Armistead et al., 2020
|
caudal fin epidermal cell aggregated, ameliorated
|
WT + MO1-spint1a + MO1-st14a + MO3-lama5
|
control
|
Fig. 5
from Armistead et al., 2020
|
epidermal basal stratum cell protruding out of epidermis, ameliorated
|
WT + MO1-spint1a + MO1-st14a + MO3-lama5
|
control
|
Fig. 5
from Armistead et al., 2020
|
peridermal cell protruding out of epidermis, ameliorated
|
WT + MO1-spint1a + MO1-st14a + MO3-lama5
|
control
|
Fig. 5
from Armistead et al., 2020
|
epithelial cell protruding out of epidermal superficial stratum, ameliorated
|
cy22Tg + MO1-spint1a + MO1-st14a
|
standard conditions
|
Fig. 3
from Schepis et al., 2018
|
epithelial cell protruding out of epidermal superficial stratum, abnormal
|
cy34Tg + MO1-erbb2 + MO1-spint1a
|
standard conditions
|
Fig. 8
from Schepis et al., 2018
|
epidermal basal stratum cell population proliferation occurrence, ameliorated
|
cy34Tg + MO1-erbb2 + MO1-spint1a
|
standard conditions
|
Fig. 8
from Schepis et al., 2018
|
epidermal superficial stratum cell population proliferation increased occurrence, abnormal
|
cy34Tg + MO1-erbb2 + MO1-spint1a
|
standard conditions
|
Fig. 8
from Schepis et al., 2018
|
epidermal superficial stratum cell population proliferation occurrence, ameliorated
|
cy34Tg + MO1-spint1a + MO1-st14a
|
standard conditions
|
Fig. 6
from Schepis et al., 2018
|
epidermal basal stratum cell motility occurrence, ameliorated
|
cy34Tg + MO1-spint1a + MO1-st14a
|
standard conditions
|
Fig. 6
from Schepis et al., 2018
|
epithelial cell protruding out of epidermal superficial stratum, abnormal
|
cy34Tg + MO1-spint1a + MO2-mmp9 + MO3-mmp9
|
standard conditions
|
Fig. 7
from Schepis et al., 2018
|
epithelial cell protruding out of epidermal superficial stratum, abnormal
|
cy34Tg + MO1-spint1a + MO2-mmp9 + MO3-mmp9
|
chemical treatment: matrix metalloproteinase inhibitor
|
Fig. 7
from Schepis et al., 2018
|
epithelial cell protruding out of epidermal superficial stratum, ameliorated
|
f2rl1.2sfc18b/sfc18b; cy22Tg + MO1-spint1a
|
standard conditions
|
Fig. 3
from Schepis et al., 2018
|
epidermal basal stratum cell motility occurrence, ameliorated
|
f2rl1.2sfc18b/sfc18b; cy34Tg + MO1-spint1a
|
standard conditions
|
Fig. 6
from Schepis et al., 2018
|
epithelial cell protruding out of epidermal superficial stratum, ameliorated
|
f2rl1.2sfc18b/sfc18b; cy34Tg + MO1-spint1a
|
chemical treatment: PD 168393
|
Fig. 8
from Schepis et al., 2018
|
epidermal superficial stratum cell population proliferation occurrence, ameliorated
|
f2rl1.2sfc18b/sfc18b; cy34Tg + MO1-spint1a
|
chemical treatment: PD 168393
|
Fig. 8
from Schepis et al., 2018
|
epidermal basal stratum cell population proliferation occurrence, ameliorated
|
f2rl1.2sfc18b/sfc18b; cy34Tg + MO1-spint1a
|
chemical treatment: PD 168393
|
Fig. 8
from Schepis et al., 2018
|
epidermal basal stratum cell-cell junction ab2-cdh1 labeling position, ameliorated
|
f2rl1.2sfc18b/sfc18b; cy34Tg + MO1-spint1a
|
standard conditions
|
Fig. 5
from Schepis et al., 2018
|
epidermal basal stratum cell population proliferation occurrence, ameliorated
|
f2rl1.2sfc18b/sfc18b; cy34Tg + MO1-spint1a
|
standard conditions
|
Fig. 8
from Schepis et al., 2018
|
epidermal superficial stratum cell population proliferation increased occurrence, exacerbated
|
f2rl1.2sfc18b/sfc18b; cy34Tg + MO1-spint1a
|
standard conditions
|
Fig. 6 ,
Fig. 8
from Schepis et al., 2018
|
epithelial cell protruding out of epidermal superficial stratum, ameliorated
|
f2rl1.2sfc18b/sfc18b; cy34Tg + MO1-spint1a
|
standard conditions
|
Fig. 8
from Schepis et al., 2018
|
epidermal basal stratum cell-cell adhesion process quality, ameliorated
|
f2rl1.2sfc18b/sfc18b; la213Tg; mu271Tg + MO1-spint1a
|
standard conditions
|
Fig. 4
from Schepis et al., 2018
|
epidermal basal stratum cell motility occurrence, ameliorated
|
f2rl1.2sfc18b/sfc18b; la213Tg; mu271Tg + MO1-spint1a
|
standard conditions
|
Fig. 4
from Schepis et al., 2018
|
epidermal basal stratum cell-cell adhesion process quality, ameliorated
|
la213Tg; mu271Tg + MO1-spint1a + MO1-st14a
|
standard conditions
|
Fig. 4
from Schepis et al., 2018
|
epidermal basal stratum cell motility occurrence, ameliorated
|
la213Tg; mu271Tg + MO1-spint1a + MO1-st14a
|
standard conditions
|
Fig. 4
from Schepis et al., 2018
|
epithelial cell protruding out of epidermal superficial stratum, ameliorated
|
f2rl1.2sfc18b/sfc18b; cy34Tg + MO1-erbb2 + MO1-spint1a
|
standard conditions
|
Fig. 8
from Schepis et al., 2018
|
epidermal superficial stratum cell population proliferation occurrence, ameliorated
|
f2rl1.2sfc18b/sfc18b; cy34Tg + MO1-erbb2 + MO1-spint1a
|
chemical treatment: PD 168393
|
Fig. 8
from Schepis et al., 2018
|
epidermal basal stratum cell population proliferation occurrence, ameliorated
|
f2rl1.2sfc18b/sfc18b; cy34Tg + MO1-erbb2 + MO1-spint1a
|
chemical treatment: PD 168393
|
Fig. 8
from Schepis et al., 2018
|
epidermal basal stratum cell motility occurrence, ameliorated
|
f2rl1.2sfc18b/sfc18b; cy34Tg + MO1-spint1a + MO1-st14a
|
standard conditions
|
Fig. 6
from Schepis et al., 2018
|
epidermal superficial stratum cell population proliferation increased occurrence, ameliorated
|
f2rl1.2sfc18b/sfc18b; cy34Tg + MO1-spint1a + MO1-st14a
|
standard conditions
|
Fig. 6
from Schepis et al., 2018
|